Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Q-linea ABCHIX:QLINES 66 Earnings per Share (Diluted) is kr-13.20 as of Jun. 2026. GuruFocus rates CHIX:QLINES with a GF Score™ of 66/100 and a GF Value™ of kr1,776.96. The stock has 3 warning signs investors should review. Among 658 Medical Devices & Instruments companies, Q-linea AB ranks better than 94.38% on this metric.
Q-linea AB's EPS (Basic) for the
three
months ended in Jun. 2026 was kr-1.58.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was kr-13.20.
Q-linea AB's EPS without NRI for the
three
months ended in Jun. 2026 was kr-1.68.
Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was kr-13.51.
During the past 3 years, the average EPS without NRIGrowth Rate was 71.50% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 72.60% per year.
During the past 11 years, Q-linea AB's highest 3-Year average EPS without NRI Growth Rate was 94.30% per year. The lowest was -44.20% per year. And the median was 2.40% per year.
Q-linea AB (CHIX:QLINEs) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Q-linea AB Earnings per Share (Diluted) Related Terms
Q-linea AB Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Q-linea AB's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:QLINES vs ABT, SYK, MDT: Earnings per Share (Diluted) Comparison
For the Medical Devices subindustry, Q-linea AB's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-linea AB PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-linea AB's PE Ratio distribution charts can be found below:
* The bar in red indicates where Q-linea AB's PE Ratio falls into.
Q-linea AB Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Q-linea AB's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-13.20
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of kr-13.20 mean?
Q-linea AB (CHIX:QLINES) has a Earnings per Share (Diluted) of kr-13.20 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Q-linea AB and its competitors. According to the industry distribution chart, Q-linea AB ranks #37 out of 658 companies in the Medical Devices & Instruments industry, placing it in the top 5.6%.
Is Q-linea AB's Earnings per Share (Diluted) too high?
Q-linea AB's current Earnings per Share (Diluted) is kr-13.20. Based on the distribution chart, Q-linea AB ranks #37 out of 658 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Q-linea AB has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Q-linea AB's Earnings per Share (Diluted) compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-linea AB ranks #37 out of 658 companies for Earnings per Share (Diluted). This places Q-linea AB in the top 6% of its industry — outperforming the majority of peers. The industry median Earnings per Share (Diluted) is 8.05. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Devices & Instruments company?
The median Earnings per Share (Diluted) among Medical Devices & Instruments companies is 8.05, based on 658 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Q-linea AB and its competitors. For the Medical Devices & Instruments industry, the median Earnings per Share (Diluted) is 8.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-linea AB's current Earnings per Share (Diluted) is kr-13.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-linea AB stock overvalued right now?
Q-linea AB (CHIX:QLINES) has a current Earnings per Share (Diluted) of kr-13.20. The stock's GF Value™ is kr1,776.96, compared to a current price of kr1,610.00 — trading 9.4% below its estimated fair value. The current Earnings per Share (Diluted) is kr-13.20. Q-linea AB's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Q-linea AB (CHIX:QLINES), the current Earnings per Share (Diluted) is kr-13.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Q-linea AB (CHIX:QLINES) Overvalued in 2026?
Based on GuruFocus' analysis, Q-linea AB stock appears to be undervalued.
The current stock price of kr1,610.00 is trading 9.4% below its estimated GF Value™ of kr1,776.96.
Key valuation signals for CHIX:QLINES:
Earnings per Share (Diluted): kr-13.20
GF Value™: kr1,776.96 vs. price of kr1,610.00 (9.4% below fair value)
No single metric tells the full story. See the CHIX:QLINES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Q-linea AB is a company that develops infection diagnostics solutions that benefit patients, healthcare providers, and society, enabling rapid diagnosis of blood infections such as sepsis within six hours of a positive blood culture. It focuses on developing instruments and consumables that benefit patients, healthcare providers, and society. It develops and delivers solutions for healthcare providers, enabling them to diagnose and treat infectious diseases in the shortest possible time. The company's product, ASTar, is a fully automated instrument (AST, antibiotic susceptibility testing), which produces a sensitivity profile from a positive blood culture.
66GF Score
Get the complete analysis for CHIX:QLINES
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:QLINES has been successfully added to your 
